Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography

Coronary Artery Disease Clinical Trial

— SAFE-CT  

Official title:

Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06438393
• Other study ID #: SAFE-CT
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: December 2027

Study information

• Verified date: February 2024
• Source: Universidade do Porto
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project aims to improve direct patient care by reducing the risks of futile exposure to ionizing radiation and iodinated contrast in patients referred for coronary computed tomography angiography

Description:

Since the last NICE guidelines update recommending computed tomography coronary angiography (CTCA) as the first line of investigation for patients with suspected coronary artery disease (CAD), there has been a high burden in the healthcare system and unnecessary exposition to radiation and iodine-containing contrast medium, especially in the youngest. Around 35% of patients who currently undergo CTCA have normal coronaries which means those patients were unnecessary exposed to radiation and contrast. A CTCA screening strategy to rule out CAD is needed to comply with the ALARA ("As Low As Reasonable Achievable") principles preventing radiation risks, reducing unnecessary scans and directing healthcare resources to those who will benefit from a CTCA. We designed the SAFE-CT (Screening coronary Artery disease using artiFicial intelligencE in noncontrast Computed Tomography) study to develop a state-of-art artificial intelligence method to detect CAD as defined on CTCA using high-dimensional data (radiomics) extracted from the non-contrast cardiac computed tomography (CT). The model will be trained in 15,000 subjects scanned with paired non-contrast CT and CTCA and externally validated in an independent cohort of 1,000 subjects. In a preliminary analysis, non-contrast CT radiomics improved calcium score performance and discriminated CAD with an AUC of 0.91 (95% CI: 0.83-1.00). The algorithm will be converted into a user-friendly plugin to automatically decide whether the patient needs contrast. A real-world multicentre cohort study will be planned for software prospective validation and the creation of a large-scale proteomic biobank to support the translation of imaging biomarkers worldwide. SAFE-CT can change the current CT scanning workflow by creating software that accurately rules out any CAD in >1/3 of patients referred for CTCA with low radiation and no contrast. This accurate machine learning model will be optimized to reach >90% sensitivity and negative predictive value and will bring several advantages for patients and the healthcare system: - Prevention of radiation and contrast exposition. - Increased CTCA scanning capacity for complex cases. - Widespread use of CT for CAD exclusion in the emergency department and in outpatient clinics of centres with no CTCA. - Improved screening tool for CAD in asymptomatic subjects. - Up- and downstream cost reduction. The SAFE-CT project proposes a safer, low-cost, and personalized CTCA scanning strategy that fosters scientific and technological innovation with the potential to bring improvement to patient care and clinical practice, and, thereby, societal, and economic impact.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1000
• Est. completion date: December 2027
• Est. primary completion date: June 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patient with stable chest pain who underwent a CTCA

Exclusion Criteria:

• Missing non-contrast CT image (coronary calcium score image)
• Known coronary artery disease
• Prior myocardial infarction
• Prior PCI or CABG

Related Conditions & MeSH terms

• Atherosclerosis
• Coronary Artery Disease
• Coronary Atheroscleroses
• Coronary Disease
• Myocardial Ischemia

Intervention

Diagnostic Test:
• CT coronary angiography and non-contrast CT
A CTCA is an X-ray computed tomography of the coronary arteries that allows visualization of coronary plaques with high temporal and spatial resolution, however, it implies the use of iodine contrast and exposition to clinically significant ionizing radiation. Non-contrast ECG-gated CT ("calcium score" - CCS image). A non-contrast cardiac CT for CCS can be performed very quickly with significantly lower radiation (~6 times lower) than CTCA and without the need for contrast.

Locations

Country	Name	City	State
Portugal	Faculty of Medicine of Porto	Porto

Sponsors (3)

Lead Sponsor	Collaborator
Universidade do Porto	University of Edinburgh, University of Oxford

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Build a non-contrast CT radiomic signature of CAD		3 years
Primary	Implement a machine learning model to discriminate patients with no CAD from patients with at least minimal disease (CAD-RADS=0 vs. CAD-RADS>0).		3 years
Primary	Implement a machine learning model to detect coronary inflammation as defined using the Fat Attenuation Index (FAI = -70.1 HU) in patients with no visible coronary plaque (CAD-RADS=0).		3 years
Primary	Build a user-friendly plugin to facilitate users experience and distribution of our technology in clinical practice.		3 years
Primary	Evaluate the real-world operationality and performance of the plugin in an international multicentre prospective cohort study.		3 years
Primary	Create a national registry of cardiac CT		3 years
Secondary	Setup a human blood biobank to identify the peripheral blood mononuclear cells (PBMCs) and plasma proteomics associated with CT data and clinical outcomes.		3 years
Secondary	Setup a public CT imaging repository		3 years